A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi

doi:10.1007/BF00175402

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

P. Presgrave^*, R. Woods, R. Kefford, D. Bell, D. Raghavan, J. Levi

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

4′ Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m² and 40 mg/m² respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc < 3 × 10⁹/L occurred in 33% of patients and thrombocytopenia < 100 × 10⁹/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.

Original language	English
Pages (from-to)	219-221
Number of pages	3
Journal	Investigational New Drugs
Volume	6
Issue number	3
DOIs	https://doi.org/10.1007/BF00175402
Publication status	Published - Sep 1988
Externally published	Yes

Keywords

4′demethoxydaunorubicin
non small cell lung cancer
oral
phase II

Access to Document

10.1007/BF00175402

Cite this

@article{a922d32a16d04c82a05035b65d558244,

title = "A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer",

abstract = "4′ Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m2 and 40 mg/m2 respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc < 3 × 109/L occurred in 33% of patients and thrombocytopenia < 100 × 109/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.",

keywords = "4′demethoxydaunorubicin, non small cell lung cancer, oral, phase II",

author = "P. Presgrave and R. Woods and R. Kefford and D. Bell and D. Raghavan and J. Levi",

year = "1988",

month = sep,

doi = "10.1007/BF00175402",

language = "English",

volume = "6",

pages = "219--221",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "KLUWER ACADEMIC PUBL",

number = "3",

}

TY - JOUR

T1 - A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

AU - Presgrave, P.

AU - Woods, R.

AU - Kefford, R.

AU - Bell, D.

AU - Raghavan, D.

AU - Levi, J.

PY - 1988/9

Y1 - 1988/9

N2 - 4′ Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m2 and 40 mg/m2 respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc < 3 × 109/L occurred in 33% of patients and thrombocytopenia < 100 × 109/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.

AB - 4′ Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m2 and 40 mg/m2 respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc < 3 × 109/L occurred in 33% of patients and thrombocytopenia < 100 × 109/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.

KW - 4′demethoxydaunorubicin

KW - non small cell lung cancer

KW - oral

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=0023770996&partnerID=8YFLogxK

U2 - 10.1007/BF00175402

DO - 10.1007/BF00175402

M3 - Article

C2 - 2847993

AN - SCOPUS:0023770996

VL - 6

SP - 219

EP - 221

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this